Paper Details

  1. Home
  2. Paper Details

Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells.

Author: SlotmanBen J, Van Den BergJaap, Van RijnJohannes, van NifterikKrista A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that the combination of temozolomide (TMZ) and meloxicam (MLC) resulted in a significant potentiation of their cytotoxicity in D384 and Hs683 human glioma cell lines. The combination of these two drugs can also cause considerable enhancement of the radiation response in human glioma cell lines.
Paper Details　
Original Abstract of the Article :
PURPOSE: To investigate the possible cytotoxic interactions between the chemotherapeutic drug temozolomide (TMZ) and the cyclooxygenase-2 inhibitor meloxicam (MLC) or of both drugs combined with X-rays in three human glioma cell lines (D384, Hs 683 and U251). MATERIALS AND METHODS: Cells were expos...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/09553002.2010.519423

データ提供：米国国立医学図書館（NLM）

A Multimodal Approach to Glioma Treatment: Combining Chemotherapy, COX-2 Inhibition, and Radiation

The fight against cancer is constantly evolving, with researchers exploring innovative treatment strategies to improve patient outcomes. This study focuses on the potential benefits of combining different treatment modalities in the management of glioma, a type of brain tumor. The researchers employed a combination of chemotherapy (temozolomide), COX-2 inhibition (meloxicam), and X-rays to target glioma cells in vitro. This study offers valuable insights into the synergistic effects of these treatments, providing a potential pathway towards more effective glioma therapies.

Synergistic Effects for Enhanced Glioma Treatment

This study suggests that combining temozolomide, meloxicam, and X-rays may be a promising approach to treating glioma. The researchers observed a significant increase in cytotoxicity when these treatments were combined, highlighting their synergistic effects. The study suggests that this multimodal approach may lead to improved patient outcomes and increased survival rates.

The Promise of Combined Therapies for Glioma Treatment

This research offers a potential avenue for developing more effective treatment strategies for glioma. The study's findings encourage further investigation into the synergistic effects of combining chemotherapy, COX-2 inhibition, and radiation. These insights may lead to the development of new treatment protocols that offer greater efficacy and improved outcomes for glioma patients.

Dr. Camel's Conclusion

This study on glioma treatment is like a caravan crossing a vast desert, seeking the most effective route to conquer this challenging disease. The researchers combined different treatment modalities, much like the caravan combined its resources, to create a powerful force against glioma. This study, like a desert oasis, offers hope for patients facing this formidable foe.

Date :
  1. Date Completed 2011-03-11
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

21067299

DOI: Digital Object Identifier

10.3109/09553002.2010.519423

Related Literature

Article Analysis
・Effects of temozolomide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.